Similar Papers

Paper Title
Journal
Date
Author
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor
John Mascarenhas ... Srdan Verstovsek
Blood | VOL. 136
John Mascarenhas, et. al.John Mascarenhas ... Srdan Verstovsek
05 Nov 2020
A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis
Harinder Gill ...
Blood | VOL. 138
Harinder Gill, et. al.Harinder Gill ...
05 Nov 2021
Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment
Muhamed Baljevic ...
Blood | VOL. 138
Muhamed Baljevic, et. al.Muhamed Baljevic ...
05 Nov 2021
HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics-Subgroup Analysis
...
Blood | VOL. 136
, et. al. ...
05 Nov 2020
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Reactive oxygen species regulate early development of the intestinal macrophage-microbiome interface.
Zohreh Mansoori Moghadam ... Philipp Henneke
Blood | VOL. -
Zohreh Mansoori Moghadam, et. al.Zohreh Mansoori Moghadam ... Philipp Henneke
03 Feb 2025
Deficiency of T follicular helper cell Tet3 DNA demethylation inhibits pathogenic IgG2c class switching and chronic GVHD.
Michael C Zaiken ... Bruce R Blazar
Blood | VOL. -
Michael C Zaiken, et. al.Michael C Zaiken ... Bruce R Blazar
03 Feb 2025
How I approach pharmacological thromboprophylaxis in children.
Anthony A Sochet ... Neil A Goldenberg
Blood | VOL. -
Anthony A Sochet, et. al.Anthony A Sochet ... Neil A Goldenberg
03 Feb 2025
IL-10 from tumoral B cells modulates the diffuse large B-cell lymphoma microenvironment and response to immunotherapy.
Marcos Garcia-Lacarte ... Sergio Roa
Blood | VOL. -
Marcos Garcia-Lacarte, et. al.Marcos Garcia-Lacarte ... Sergio Roa
03 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.